dexamethasone,cc-99285,cc-99282,rituximab,iberdomide,lisocabtagene maraleucel,obinutuzumab
merck,roche,bms
['nhl-001', 'cc,220,dlbcl,001', 'dlbcl', 'iberdomide', 'cc,220,mm,001', ' iber ', 't-cell lymphoma', 'obinu', 'cc,220,nhl,001', 'fil,veral,12', 'cc-220', '#233', 'ritux', '220,mm,001', 'nhl', 'celmod', '220,dlbcl,001', 'lymphoma', 'lymsm', 'bms', 'marker ', 'bristol']
congress | #ash22 of presents early results from the phase i/ii study of iberdomide rituximab/obinutuzumab in r/r #lymphoma. iberdomide alone and in combination with anti-cd20 mabs showed promising activity in this patient group. #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm